amobarbital has been researched along with Adrenal Gland Hypofunction in 2 studies
Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berton, AM | 1 |
| Prencipe, N | 1 |
| Giordano, R | 1 |
| Ghigo, E | 1 |
| Grottoli, S | 1 |
| Grote, CL | 1 |
| Meador, K | 1 |
2 other studies available for amobarbital and Adrenal Gland Hypofunction
| Article | Year |
|---|---|
Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Amobarbital; Anti-Inflammatory Agents; COVID-19; COV | 2021 |
Has amobarbital expired? Considering the future of the Wada.
Topics: Adrenal Insufficiency; Amobarbital; Anesthetics, Intravenous; Cerebral Cortex; Epilepsy; Functional | 2005 |